TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17338710

Group type: EXPERIMENTAL
Intervention: NID 12 (12 of 16 intervals)
Number of subjects: 875

Group type: COMPARATOR
Intervention: NID 18 (18 of 24 intervals)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Hypothetical NID 18 for NID 12 patients
Number of subjects: 875

Group type: COMPARATOR
Intervention: Hypothetical NID 12 for NID 18 patients
Number of subjects: 875
Study: 15037050

Group type: EXPERIMENTAL
Intervention: Haptic face recognition
Number of subjects: 1

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 1
Study: 10655193

Group type: EXPERIMENTAL
Intervention: Mepivacaine (2%, 0.4 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mepivacaine vs Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 50
Study: 8882471

Group type: EXPERIMENTAL
Intervention: Metronidazole and tripotassium dicitrato bismuthate combined with ranitidine and antacid (group 1)
Number of subjects: 736

Group type: COMPARATOR
Intervention: Ranitidine and antacid (group 2)
Number of subjects: 736

Group type: COMPARATOR
Intervention: H2-receptor antagonist and antacid (group 3, H. pylori-negative patients)
Number of subjects: 736
Study: 1986509

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air (16% oxygen)
Number of subjects: 14
Study: 6669871

Group type: EXPERIMENTAL
Intervention: Conservative treatment (rest in splints, non‐steroidal anti‐inflammatory drugs, gold or anti‐malaria agent) for 4-5 months
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Synovectomy surgery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (non-surgical treatment)
Number of subjects: 121

Group type: COMPARATOR
Intervention: All patients (surgical and conservative treatment)
Number of subjects: 121
Study: 31535367

Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29405368

Group type: EXPERIMENTAL
Intervention: Proactive telephone support (daily calls for up to 14 days after discharge)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Control group (could initiate telephone contact themselves)
Number of subjects: 493
Study: 26028355

Group type: EXPERIMENTAL
Intervention: Enhanced behavioral counseling (FRESH)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced standard care (control)
Number of subjects: 300
Study: 22828087

Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventional Manual Office Blood Pressure (MOBP)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: AOBP
Number of subjects: 252

Group type: COMPARATOR
Intervention: MOBP
Number of subjects: 252
Study: 19622200

Group type: EXPERIMENTAL
Intervention: Exposure to the letter A before a task
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Exposure to the letter F before a task
Number of subjects: 131

Group type: COMPARATOR
Intervention: Exposure to the neutral letter J (control condition) in Expt 2
Number of subjects: 131
Study: 18403742

Group type: EXPERIMENTAL
Intervention: SMART Arm with electromyography‐triggered electrical stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SMART Arm alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 42
Study: 15809569

Group type: EXPERIMENTAL
Intervention: 10K group (10,000 steps per day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 30‐min group (brisk 30‐min walk)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 30‐min group (on days with a 30-min walk)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 30‐min group (on days without a 30-min walk)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10K group (on days with at least 10,000 steps)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10K group (on days without achieving target)
Number of subjects: 58
Study: 12096707

Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation program including physician advice, bedside education and counseling, take-home materials, nicotine replacement therapy, and post-discharge counseling calls.
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation program
Number of subjects: 2091
Study: 10671699

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8906007

Group type: EXPERIMENTAL
Intervention: Nasal spray bromocriptine (0.8 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1679444

Group type: EXPERIMENTAL
Intervention: Chlorhexidine with a single-use brush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 0
Study: 6498122

Group type: EXPERIMENTAL
Intervention: Moderate short-term maternal exercise (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 28
Study: 30801983

Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement (TDR) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse-led behavioral support
Number of subjects: 0
Study: 30558159

Group type: EXPERIMENTAL
Intervention: WB+BM− (Wheat Bran without Barley)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: WB−BM+ (Barley without Wheat Bran)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: WB+BM+ (Wheat Bran and Barley)
Number of subjects: 60

Group type: COMPARATOR
Intervention: WB−BM− (Control group with neither Wheat Bran nor Barley)
Number of subjects: 60
Study: 26830468

Group type: EXPERIMENTAL
Intervention: DAS181 (10 mg administered via dry particle inhaler on 3 consecutive days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25332321

Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation (1.5 g LC n-3 PUFAs/d)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 84
Study: 22302719

Group type: EXPERIMENTAL
Intervention: Letrozole (10 mg daily for 3 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo for 3 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Letrozole and Control
Number of subjects: 30
Study: 20485335

Group type: EXPERIMENTAL
Intervention: Varenicline (1.0 mg b.i.d.)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 17111121

Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bioabsorbable membrane (BM group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 17562750

Group type: EXPERIMENTAL
Intervention: Rate soothing algorithm
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ventricular rate stabilization algorithm
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: All on (rate soothing + ventricular rate stabilization + post-AF response)
Number of subjects: 182

Group type: COMPARATOR
Intervention: All off (DDD 60)
Number of subjects: 182
Study: 15550166

Group type: EXPERIMENTAL
Intervention: Two-day small group seminar on medical interviewing
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 105
Study: 11004108

Group type: EXPERIMENTAL
Intervention: Head mounted perimetry system
Number of subjects: 37

Group type: COMPARATOR
Intervention: Confrontation visual field testing
Number of subjects: 37
Study: 9178384

Group type: EXPERIMENTAL
Intervention: Mechanical CPR (M-CPR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual Standard CPR (S-CPR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active Compression-Decompression CPR (ACD-CPR)
Number of subjects: 12
Study: 1491396

Group type: EXPERIMENTAL
Intervention: DecaDurabolin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: oral Ca (control)
Number of subjects: 18
Study: 3888250

Group type: EXPERIMENTAL
Intervention: Single dose of 3 g amoxycillin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional course of ampicillin over 7 days
Number of subjects: 90
Study: 30272159

Group type: EXPERIMENTAL
Intervention: Health-promoting interventions targeting social and environmental levels
Number of subjects: 35
Study: 30332482

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 μg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufentanil 2.0 μg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufentanil 2.5 μg/kg
Number of subjects: 90
Study: 27207411

Group type: EXPERIMENTAL
Intervention: DDS-1 strain of Lactobacillus acidophilus (1 dose daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 1 dose daily for 4 weeks)
Number of subjects: 0
Study: 24686106

Group type: EXPERIMENTAL
Intervention: Combined use of interferon beta‐1a and glatiramer acetate
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Interferon beta‐1a alone
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Glatiramer acetate alone
Number of subjects: 1008
Study: 22331758

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50-mg tablets (test formulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bicalutamide 50-mg tablets (reference formulation)
Number of subjects: 40
Study: 20558755

Group type: EXPERIMENTAL
Intervention: L-NAME + ketorolac infusion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-NAME infusion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control values
Number of subjects: 13
Study: 17377860

Group type: EXPERIMENTAL
Intervention: Leukodepletion (group A: n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (group B: n = 25)
Number of subjects: 50
Study: 15617967

Group type: EXPERIMENTAL
Intervention: Primary closure technique (Group 1) - hermetically suturing the flap
Number of subjects: 200

Group type: COMPARATOR
Intervention: Secondary closure technique (Group 2) - removal of a 5-6 mm wedge of mucosa for secondary healing
Number of subjects: 200
Study: 11891832

Group type: EXPERIMENTAL
Intervention: Methotrexate (5 to 20mg per week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10213296

Group type: EXPERIMENTAL
Intervention: MM + MNF (multi-nutrient fortifier)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MM + CaGP (calcium and phosphorus alone)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-MM (mother's milk feeding group to 6 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-FF (formula feeding group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: PTF (preterm formula)
Number of subjects: 25
Study: 8536087

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum consumption after meals (study group)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Xylitol chewing gum consumption after meals (control group)
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Daily use of xylitol chewing gum (study group)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Daily use of xylitol chewing gum (control group)
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Knowledge about xylitol (study group)
Number of subjects: 1281
Study: 2798632

Group type: EXPERIMENTAL
Intervention: Artificial daylight (2500 lux) from 20.00 to 23.00 and from 07.00 to 10.00 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Red light (300 lux) from 20.00 to 23.00 and from 07.00 to 10.00 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Artificial daylight (2500 lux) from 22.00 to 23.00 and from 07.00 to 08.00 hours
Number of subjects: 10
Study: 334336

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31015587

Group type: EXPERIMENTAL
Intervention: 150 mg of levodopa
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29906570

Group type: EXPERIMENTAL
Intervention: FOND-O (Fosaprepitant, Ondansetron, Dexamethasone + Olanzapine 10 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: FOND (Fosaprepitant, Ondansetron, Dexamethasone)
Number of subjects: 101
Study: 27713633

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic procedure (n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open surgical procedure (n=16)
Number of subjects: 30
Study: 25414047

Group type: EXPERIMENTAL
Intervention: PS+PA (300 mg PS + 240 mg PA/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 22309303

Group type: EXPERIMENTAL
Intervention: SafeR
Number of subjects: 422

Group type: COMPARATOR
Intervention: DDD/AMC
Number of subjects: 422

Group type: COMPARATOR
Intervention: DDD/LD
Number of subjects: 422
Study: 21039042

Group type: EXPERIMENTAL
Intervention: Lay health worker home visit
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 234
Study: 18211754

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 'Dermatophagoides Farinae Drops' (n = 139)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo (n = 139)
Number of subjects: 278
Study: 15530583

Group type: EXPERIMENTAL
Intervention: Weight control advice
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Information on health benefits of weight loss
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Advice to increase physical activity
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Physician-delivered weight control advice
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Education about weight loss
Number of subjects: 255
Study: 12819512

Group type: EXPERIMENTAL
Intervention: Therapeutic immunization with inactivated envelope-depleted HIV-1 coupled with incomplete Freund's adjuvant (IFA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (IFA alone)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Therapeutic immunization
Number of subjects: 9
Study: 10903599

Group type: EXPERIMENTAL
Intervention: rBPI21 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (other major abdominal surgeries)
Number of subjects: 0
Study: 8752803

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times a day)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 1990951

Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg/day orally for 30 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 14
Study: 6886255

Group type: EXPERIMENTAL
Intervention: Antihistamine (4 mg of brompheniramine maleate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decongestant-antihistamine combination (4 mg of brompheniramine maleate, 5 mg of phenylephrine HCl, 5 mg of phenylpropanolamine HCl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Theophylline (premedication)
Number of subjects: 20
Study: 30610143

Group type: EXPERIMENTAL
Intervention: After-Visit Summary (AVS) provided to patients after each clinic visit
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: After-Visit Summary (AVS) provided in patients' first language
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: After-Visit Summary (AVS) meaningfulness
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Reasons for nonmeaningful AVS
Number of subjects: 250
Study: 29941497

Group type: EXPERIMENTAL
Intervention: Youth
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 421
Study: 27104905

Group type: EXPERIMENTAL
Intervention: mHealth accelerometer-based physical activity prescription
Number of subjects: 30
Study: 25262324

Group type: EXPERIMENTAL
Intervention: Push as-fast-as-you-can (PF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 100 compressions per minute (100-cpm)
Number of subjects: 42
Study: 22162508

Group type: EXPERIMENTAL
Intervention: valproic acid (300 mg bid) with early or late addition of lacosamide (200 mg bid)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: lacosamide (200 mg bid) with early or late addition of valproic acid (300 mg bid)
Number of subjects: 32
Study: 20237130

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the posterior hypothalamus
Number of subjects: 10
Study: 17346530

Group type: EXPERIMENTAL
Intervention: Antibiotics (metronidazole plus azithromycin)
Number of subjects: 241
Study: 15709825

Group type: EXPERIMENTAL
Intervention: Inflated responsibility in the context of negative mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inflated responsibility alone
Number of subjects: 0
Study: 11903074

Group type: EXPERIMENTAL
Intervention: Amino acid-treated propofol group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amino acid-treated isoflurane group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane-based anesthesia without amino acids
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-based anesthesia without amino acids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amino acid-treated groups (both propofol and isoflurane)
Number of subjects: 40
Study: 9625544

Group type: EXPERIMENTAL
Intervention: 3.2-mm incision
Number of subjects: 111

Group type: COMPARATOR
Intervention: 5.5-mm incision
Number of subjects: 111
Study: 7942354

Group type: EXPERIMENTAL
Intervention: Mefloquine (750 mg given immediately, followed by 500 mg 6 h later) with tetracycline (250 mg four times daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Quinine (600 mg every 8 h for seven days) with tetracycline (250 mg four times daily)
Number of subjects: 102
Study: 3203964

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 24-hour diagnostic continuous electrocardiographic and high fidelity arterial pressure monitoring in hypertensive group (n=7)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 24-hour diagnostic continuous electrocardiographic and high fidelity arterial pressure monitoring
Number of subjects: 11
Study: 31415392

Group type: EXPERIMENTAL
Intervention: Individualized occlusal splint therapy applied during day‐ and nighttime plus usual care (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care alone (n=30)
Number of subjects: 60
Study: 29793433

Group type: EXPERIMENTAL
Intervention: List randomization (Arm A)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Direct estimates (Arm B)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Direct estimation (Arm B)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Observed past behavior
Number of subjects: 483
Study: 26888164

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Colesevelam
Number of subjects: 19

Group type: COMPARATOR
Intervention: CDCA + colesevelam
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24065294

Group type: EXPERIMENTAL
Intervention: Combination exercise training (aerobic, strength, and stretching exercise trainings) 3 days per week for 4 weeks (12 workouts total)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 64
Study: 22520733

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy combined with bevacizumab and erlotinib
Number of subjects: 26
Study: 19862578

Group type: EXPERIMENTAL
Intervention: Provider decision support and patient decision support
Number of subjects: 7412
Study: 17928625

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Quinapril (20 mg daily)
Number of subjects: 22
Study: 15647105

Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg twice daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: PI continuation
Number of subjects: 104
Study: 11901939

Group type: EXPERIMENTAL
Intervention: Diuretic and ACE inhibitor combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitor alone
Number of subjects: 0
Study: 9853849

Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 0.0625 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 0.125 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 0.25 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 2 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 1 mg
Number of subjects: 333
Study: 8281697

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 3354872

Group type: EXPERIMENTAL
Intervention: 0.2 mg preservative-free morphine sulfate in 0.2 ml solution added to hyperbaric spinal bupivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.2 ml saline added to bupivacaine (Control)
Number of subjects: 34
Study: 18716627

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey (pHW) preterm infant formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard nonhydrolyzed whey‐casein (nHWC) preterm infant formula
Number of subjects: 80
Study: 7351070

Group type: EXPERIMENTAL
Intervention: Ethmozin 225 mg/day (Group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ethmozin 600 mg/day (Group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (single-blind, only to responders)
Number of subjects: 37
Study: 30946599

Group type: EXPERIMENTAL
Intervention: Gene-family environment interactions (G×FE) message
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Genetics only message
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Family environment only message
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control article
Number of subjects: 324
Study: 28215945

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 1.5g/d for 6 months and prednisone, 0.4 to 0.6mg/kg/d for 2 months, then tapered by 20% per month for the next 4 months
Number of subjects: 176

Group type: COMPARATOR
Intervention: Prednisone, 0.8 to 1.0mg/kg/d for 2 months, then tapered by 20% per month for the next 4 months
Number of subjects: 176
Study: 26415375

Group type: EXPERIMENTAL
Intervention: Levofloxacin (750 mg once daily for 10 days)
Number of subjects: 40